Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Por Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M
Publicado no Lancet Oncol (2019)